Literature DB >> 21970838

Metabolism of novel anti-HIV agent 3-cyanomethyl-4-methyl-DCK by human liver microsomes and recombinant CYP enzymes.

Xiao-mei Zhuang1, Jing-ting Deng, Hua Li, Wei-li Kong, Jin-xiu Ruan, Lan Xie.   

Abstract

AIM: To investigate the metabolism of 3-cyanomethyl-4-methyl-DCK (CMDCK), a novel anti-HIV agent, by human liver microsomes (HLMs) and recombinant cytochrome P450 enzymes (CYPs).
METHODS: CMDCK was incubated with HLMs or a panel of recombinant cytochrome P450 enzymes including CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4, and 3A5. LC-ion trap mass spectrometry was used to separate and identify CMDCK metabolites. In the experiments with recombinant cytochrome P450 enzymes, specific chemical inhibitors combined with CYP antibodies were used to identify the CYP isoforms involved in CMDCK metabolism.
RESULTS: CMDCK was rapidly and extensively metabolized by HLMs. Its intrinsic hepatic clearance estimated from the in vitro data was 19.4 mL·min(-1)·kg(-1), which was comparable to the mean human hepatic blood flow rate (20.7 mL·min(-1)·kg(-1)). The major metabolic pathway of CMDCK was oxidation, and a total of 14 metabolites were detected. CYP3A4 and 3A5 were found to be the principal CYP enzymes responsible for CMDCK metabolism.
CONCLUSION: CMDCK was metabolized rapidly and extensively in human hepatic microsomes to form a number of oxidative metabolites. CYP3A4 and 3A5 were the predominant enzymes responsible for the oxidation of CMDCK.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21970838      PMCID: PMC4010078          DOI: 10.1038/aps.2011.91

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  25 in total

1.  Validation of a semi-automated human hepatocyte assay for the determination and prediction of intrinsic clearance in discovery.

Authors:  Anita Reddy; Tycho Heimbach; Sascha Freiwald; Danielle Smith; Roger Winters; Steven Michael; Narayanan Surendran; Hongliang Cai
Journal:  J Pharm Biomed Anal       Date:  2005-02-23       Impact factor: 3.935

2.  Development and preclinical studies of broad-spectrum anti-HIV agent (3'R,4'R)-3-cyanomethyl-4-methyl-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (3-cyanomethyl-4-methyl-DCK).

Authors:  Lan Xie; Huan-Fang Guo; Hong Lu; Xiao-Mei Zhuang; An-Ming Zhang; Gang Wu; Jin-Xiu Ruan; Ting Zhou; Donglei Yu; Keduo Qian; Kuo-Hsiung Lee; Shibo Jiang
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

Review 3.  Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes.

Authors:  A D Rodrigues
Journal:  Biochem Pharmacol       Date:  1999-03-01       Impact factor: 5.858

Review 4.  Physiological parameters in laboratory animals and humans.

Authors:  B Davies; T Morris
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

Review 5.  Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics.

Authors:  M Yamazaki; H Suzuki; Y Sugiyama
Journal:  Pharm Res       Date:  1996-04       Impact factor: 4.200

6.  Mechanism of action and resistant profile of anti-HIV-1 coumarin derivatives.

Authors:  Li Huang; Xiong Yuan; Donglei Yu; K H Lee; Chin Ho Chen
Journal:  Virology       Date:  2005-02-20       Impact factor: 3.616

7.  Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.

Authors:  Thomas R MacGregor; John P Sabo; Stephen H Norris; Philip Johnson; Lawrence Galitz; Scott McCallister
Journal:  HIV Clin Trials       Date:  2004 Nov-Dec

Review 8.  Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.

Authors:  Collen M Masimirembwa; Ulf Bredberg; Tommy B Andersson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.

Authors:  Weili Huang; Yvonne S Lin; Donavon J McConn; Justina C Calamia; Rheem A Totah; Nina Isoherranen; Mary Glodowski; Kenneth E Thummel
Journal:  Drug Metab Dispos       Date:  2004-09-21       Impact factor: 3.922

10.  Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice.

Authors:  Feng Li; Laiyou Wang; Grace L Guo; Xiaochao Ma
Journal:  Drug Metab Dispos       Date:  2010-01-26       Impact factor: 3.922

View more
  1 in total

1.  PQ-69, a novel and selective adenosine A1 receptor antagonist with inverse agonist activity.

Authors:  Min Lu; Bo Wang; Cheng Zhang; Xiaomei Zhuang; Mei Yuan; Haoshan Wang; Weizhang Li; Ruibin Su; Jin Li
Journal:  Purinergic Signal       Date:  2014-09-24       Impact factor: 3.765

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.